
Monster Alaska earthquake rocks state and sparks tsunami...and scientists warn it may not be over
The quake, which hit at 12:38pm local time (4:30pm ET), triggered an immediate tsunami warning for parts of coastal Alaska and rattled a vast swath of the Pacific Rim. But scientists now warn the true danger may just be beginning.
Although the shaking was felt most intensely in southern Alaska, where it struck near the Aleutian subduction zone, the energy released by the quake did not stay local.
Seismic waves, vibrations that travel through the Earth, activated seismic sensors as far east as the East Coast of the US and reaching across the ocean to Europe and parts of Asia and Africa.
While the vibrations were not strong enough to be felt by people thousands of miles away, sensitive instruments captured every pulse of the Earth's movement in real time.
Using a global network of sensors and cutting-edge computer simulations, scientists converted the raw data into animations showing how the seismic energy rippled out from the epicenter like waves from a stone thrown into water.
A yellow star marked ground zero on the map in Alaska, while red and blue dots representing seismic stations lit up one by one as the waves swept past.
In less than a minute, the tremors had reached monitoring stations across the world.
Large earthquakes are known to redistribute stress along fault lines, sometimes increasing the strain on already vulnerable zones.
If those areas are near their breaking point, the added pressure could trigger aftershocks or even fresh quakes, not just locally, but potentially in distant regions connected by geological stress transfer.
In rare cases, shifting stress can also activate entirely separate fault systems, making this kind of global disturbance more than a geological curiosity.
This happened in 1992, when a major 7.3 magnitude earthquake hit California and within hours, of the mainshock, seismic activity increased in places of the mainshock, seismic activity increased in places up to 750 miles away, including in Yellowstone National Park and western Nevada.
When an 8.8 magnitude quake rocked Chile in 2010, the seismic waves triggered activity in Mexico and Southern California.
The vibrations were captured using real-time computer simulations that convert raw seismic data into animations of Earth's movement, showing how ground motion travels outward from the epicenter.
An animation of the traveling shockwaves depicted blue and red seismic stations scattered across the map, lighting up as each recorded the powerful geological event.
The visual sequence, starting at 0.00 seconds, showed the epicenter marked with a yellow star, with a red line tracing the expanding wavefronts as they moved away from Alaska.
As time progressed from 1.97 to 64.94 seconds, the seismic waves continued their relentless expansion.
In the early stages, between 1.97 and 15.74 seconds, the waves primarily impacted the western coast of North America.
The primary waves reached seismic stations in Alaska and the Pacific Northwest, with the red line on the map illustrating their rapid advance.
This phase highlighted the immediate regional impact, where the energy of the quake was most intensely concentrated.
During the mid-stages, from 17.71 to 37.39 seconds, the seismic waves pushed further inland across the US.
The wavefronts began to reach stations in Canada and the central US, demonstrating the broadening scope of the earthquake's influence.
The red line on the map continued to extend, tracking the waves' progression as they traversed the continent.
In the later stages of the event, between 39.36 and 64.94 seconds, the seismic waves reached the East Coast and began influencing stations in Europe and Asia.
Adding to the mystery, a massive magnetic pulse was detected at the exact moment the earthquake occurred. The very second the rupture began, Earth's magnetic field showed a sharp spike.
Within hours, a G1-class geomagnetic storm developed, disrupting the planet's magnetic environment.
Strangely, this occurred despite otherwise nominal solar wind conditions, prompting researchers to question whether the quake may have played a role in triggering the storm.
While the link between earthquakes and geomagnetic activity remains poorly understood, the coincidence is striking.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Telegraph
7 hours ago
- Telegraph
The pioneering therapy that could roll back the rigours of ageing
The clock could be turned back on ageing with a groundbreaking new therapy that aims to recharge cells with 'batteries' from the placenta of newborns. Israel-based Minovia Therapeutics is the first company in the world to start testing mitochondrial transplantation in humans, which could treat incurable diseases and keep bodies younger for longer. Mitochondria are tiny compartments within cells that act like batteries, supplying the cell with the energy it needs to function. In ageing and certain diseases, the mitochondria stop working efficiently, starving the cells of energy, similar to the batteries running down in a machine. But scientists have now shown that it is possible to 'augment' cells with supercharged mitochondria from the placenta. Minovia has already completed clinical trials of the new therapy for patients with Pearson's Syndrome - a mitochondrial disease - and is planning to trial the treatment in elderly people next year. Dr Natalie Yivgi-Ohana, CEO and co-founder of Minovia, said: 'It's actually a very natural process for cells to take up mitochondria when they come in contact with them, but it was usually only one in 1000 cells that would do it. 'In the past 13 years, we've developed a method to maximise cellular take up without harming the cells or the mitochondria, so now more than 50 per cent of cells take up a significant amount of mitochondria. 'We take it from the youngest and healthiest organ, which is the placenta and which is full of super mitochondria and yet it's normally thrown away like garbage. We could find it to be the fountain of youth.' To make the therapy, scientists take the mitochondria from a healthy donated placenta and mix them with blood stem cells, which are then infused back into the patient's bloodstream. Not only do the super mitochondria help to produce more energy in cells, but they also reactivate natural quality control functions inside cells, which keep failing mitochondria at bay. So over time, the level of the body's healthy mitochondria also goes up. Last month, the company released phase 2 results for Pearson Syndrome, which can cause a range of problems in children, including failure to thrive, diabetes and neurological issues. There are currently no approved therapies for the condition, and care is only palliative, with patients dying during childhood. But the new therapy has led to marked improvements. 'Severe energy failure' 'These were all paediatric patients and they suffer severe energy failure, so they are not growing,' added Dr Yivgi-Ohana. 'It took a few months, but we have started observing improvement in their energy and less fatigue, more waking hours. We observed improvement in renal function, improvement in appetite, in growth.' Now the company is turning its attention towards ageing, and is hoping that growing older may one day be seen as a treatable disease. The company is planning to start trials of the treatment for elderly people in Israel next year and is developing biomarkers so they can test whether older people are experiencing mitochondrial dysfunction. It could even help diseases of ageing, such as Parkinson's, which is strongly linked to mitochondrial dysfunction. 'Significant in almost every disease' 'We are all going to suffer mitochondrial disease as we age,' added Dr Yivgi-Ohana. 'Ageing is not considered a disease, but if we have a way to demonstrate that actually, as we age, we become mitochondrially dysfunctional, then that would be the trigger to propose a treatment. 'We want to start next year treating elderly people with mitochondrial dysfunction in longevity clinics and demonstrate that it really helps. ' She added: 'The scalability in terms of the mitochondria is unlimited, there are no limitations of placentas and the amount of mitochondria that we can harvest and cryopreserve.' 'Mitochondria are such powerful organelles, and they can transfer between cells, so their sensing and their information transfer is so significant in almost every disease that you will look at.'


Medical News Today
15 hours ago
- Medical News Today
Experimental drug eliminates aggressive breast, skin cancer in small trial
Scientists have developed a new cancer drug that can be injected directly into tumors. The treatment, an enhanced CD40 agonist, was successful in its first trial of 12 human participants. Six people in the group saw their tumors shrink, while two participants saw their cancer go completely into remission. The National Institutes of Health project that doctors will diagnose at least 2 million new cancer cases and that 600,000 people will die from cancer in 2025 in the United improving cancer death rates, this prediction highlights the need to continue developing more effective treatments. Researchers from Rockefeller University made headway in this area with the completion of their human phase 1 study. They tested a new CD40 antibody drug, 2141-V11, designed to shrink tumors and reduce side new drug had promising results, shrinking tumors in half the patients and completely eliminating cancer in two cases, while not causing serious side effects. The study appears in the journal Cancer Cell.A new approach to cancer immunotherapyMany cancer treatments exist, and sometimes treatment can be as simple as removing the tumor or lesion for localized cancers. In cases where the cancer is metastatic and has spread, more aggressive treatments are necessary. Some types of more aggressive cancer treatments include: radiation therapychemotherapyhormone American Cancer Society describes immunotherapy as a 'treatment that uses the body's immune system, usually your own, to attack cancer.' There are several types of immunotherapy, such as immune checkpoint inhibitors, CAR T-cell therapy, and monoclonal antibodies. Researchers in the new study focused on immunotherapy — specifically, the CD40 agonist antibody drug class, a type of monoclonal antibody treatment. It works by activating the CD40 receptor and causing an immune system response. According to the study authors, research on CD40 has not been successful in human trials in the past and has caused serious side effects. This led the scientists to create an engineered form of CD40 called 2141-V11. The drug was designed to improve the issues with CD40 and reduce systemic inflammation and liver toxicity. The scientists also decided to inject the treatment directly into the tumor instead of administering it intravenously. For the human study, the researchers recruited 12 participants, and everyone in the group had metastatic cancers including melanoma and breast cancer. The participants ranged from ages 42 to participants received injections of 2141-V11 into their tumors every 3 weeks, with an increased dosage each results with limited toxicityThroughout the 2141-V11 treatments, the researchers monitored the side effects and bloodwork of the participants. They were especially concerned with the participants' platelet count and liver enzymes since these would indicate a treatment-related adverse event (TRAE). By the end of the treatment, ten participants experienced adverse events, and seven experienced TRAEs. However, none of the patients experienced any TRAEs higher than grade 3, and the researchers considered the drug 'well tolerated.' Most of the side effects were mild and included fever and issues where the drug was injected. Three participants had severe adverse events, but the researchers did not consider them TRAEs. One participant had to be hospitalized because of a urinary tract infection, and another had shortness of breath related to chronic heart failure. No serious dose-limiting toxicities occurred, and the participants' liver and platelet levels were stable throughout treatment. Additionally, cancer tumors shrank in six of the participants, and two participants went into complete remission. One of the participants who went into remission had melanoma, and the other had breast cancer. The researchers noted that not only did their tumors shrink, but tumors in the rest of the body disappeared. Wael Harb, MD, a board-certified hematologist and medical oncologist at MemorialCare Cancer Institute at Orange Coast and Saddleback Medical Centers, spoke with Medical News Today and explained how the cancer drug works.'This drug (2141-V11) is an engineered antibody that flips a key 'ON' switch (CD40) on immune cells inside a tumor,' said Harb, who was not involved in the recent trial. 'It's injected directly into one tumor, where it organizes immune cells into mini lymph nodes called tertiary lymphoid structures (TLS).' 'Those act like on-site training camps that activate cancer-killing T-cells, which then travel through the body to attack tumors that weren't injected,' Harb he noted that the drug's safety profile was encouraging, he emphasized that larger trials are needed. 'Twelve patients are too few to draw firm safety conclusions across cancers–larger trials are needed and are already underway,' the oncologist is next for 2141-V11?Study author Juan Osorio, MD, director Of Clinical Operations And Translational Immunology at Rockefeller University, spoke with MNT and discussed the future of the research with 2141-V11. 'We look forward to the results of several ongoing phase 2 studies nationwide, targeting difficult-to-treat cancers, such as malignant gliomas, bladder cancer, and prostate cancer,' said Osorio. Osorio mentioned that early data from the phase 2 studies is 'promising,' but it is not a one-size-fits-all solution for people with cancer. 'Not all patients respond, highlighting the need for rational combination strategies to extend the benefit of this therapy,' Osorio shared. Osorio said the team is currently trying to figure out which biomarkers may predict response to CD40 agonists. 'Furthermore, we want to evaluate in larger cohorts whether TLS or other immune spatial interactions are crucial for effective induction of antitumor immunity. Answering these questions will be critical to fully translate this approach into meaningful and durable clinical benefit for patients.'


The Independent
a day ago
- The Independent
Researchers discover the immune system's ‘fountain of youth' - but it has a cost
Researchers have discovered the 'fountain of youth' for cells - but it comes with a big cost. Some people over 60 years old were found to have immune systems that appear to much younger in wear-and-tear, Mayo Clinic researchers announced Thursday. The immune system is what protects us from getting sick and promotes healing. With age, the immune system's ability to protect the body from infection and disease can wane. Young immune systems are constantly exposed to new bacteria and viruses, and previous research has shown that infant immune systems beat those of adults at fighting off the invaders. Researchers now say some have immune systems that don't match their age. "We observed that these patients have very young immune systems despite being in their 60s and 70s,' Dr. Cornelia Weyand, a Mayo Clinic rheumatologist and clinician-scientist, said in a statement. 'But the price they pay for that is autoimmunity.' Autoimmunity is what happens when the immune system mistakenly attacks healthy tissues and organs. There are more than 100 known autoimmune diseases, according to the Cleveland Clinic, including lupus, multiple sclerosis, psoriasis, celiac disease and Hashimoto's thyroiditis. Women are at a higher risk than men, thanks to genetic and hormonal differences, according to Stanford Medicine. Doctors discovered this anomaly in more than 100 older patients who went to the Minnesota clinic to receive treatment for a rare autoimmune disease known as giant cell arteritis. Giant cell arteritis is an inflammation of the lining of your arteries that can affect the arteries in your head, the clinic explained. Untreated, it can lead to blindness, an aortic aneurysm, and, less commonly, stroke. It frequently causes headaches, jaw pain and vision problems. What causes the disorder remains unknown. Studying the diseased tissue of these patients, the researchers found they had specialized cells in their immune system known as 'stem-like T cells.' The cells behave like young stem cells, which are critical for repairing and maintaining a healthy immune system. But, in this case, they were spreading the autoimmune disease. Going forward, the scientists hope to learn more about this link and what they observed from the patients. "Contrary to what one may think, there are benefits to having an immune system that ages in tandem with the body," Dr. Jörg Goronzy, a Mayo Clinic researcher on aging, said. "We need to consider the price to pay for immune youthfulness. That price can be autoimmune disease."